receptor targets is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-08. Numbers and descriptions here follow the published literature rather than marketing material.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
多肽类化合物的表征通常依赖色谱与质谱联用技术。反相高效液相色谱用于评估纯度与有关物质，质谱用于确认分子量，肽图分析通过酶解碎片比对验证一级结构。这些手段组合使用，可以把目标产物与降解产物或类似物区分开来。单一方法往往不足以完成完整确认。
稳定性研究一般关注脱酰胺、氧化与聚集三类降解路径。脱酰胺多发生在天冬酰胺残基上，氧化常涉及甲硫氨酸与色氨酸，聚集则与浓度、温度以及容器界面接触有关。强制降解实验用于识别分子中较敏感的位点。这些结果会直接影响储存条件的设定与有效期的判断。
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
In food animals such as chickens, rabbits and pigs, some harmless strains of B. cereus are used as a probiotic feed additive to reduce Salmonella in the animals' intestines and cecum. This improves the animals' growth, as well as food safety for humans who eat them. In addition, B. cereus create and release enzymes that aid in the digestion of materials that are typically difficult to digest, such as woody plant matter, in the guts of other organisms. The strain B. cereus B25 is a biofungicide. A study by Figueroa-López et al. showed that the presence of this strain reduced Fusarium verticillioides growth. B25 shows promise for reduction of mycotoxin concentrations in grains.
Food and Drug Administration (FDA) New Dietary Ingredient (NDI) notification, evaluated under Australia's Therapeutic Goods Administration (TGA) ingredient framework, and is protected by multiple international patent applications related to banana peel extract and its applications.
== Commercial products == Several legal commercial products loosely based on the concept of "purple drank" are marketed in the United States. In June 2008, Innovative Beverage Group, a Houston, Texas-based company, released a beverage called "Drank". The commercial product contains no codeine or promethazine, but claims to "Slow Your Roll" with a combination of herbal ingredients such as valerian root and rose hips as well as the hormone melatonin. Similar "anti-energy" or relaxation drinks on the commercial market use the names "Purple Stuff", "Sippin Syrup", and "Lean". These commercial products have been criticized for their potential to serve as gateways to the dangerous illegal concoction. The marketing push has been described as akin to the making of candy cigarettes.
Duterte also received criticism after he threatened to order the military in mid-2017 to bomb Lumad schools, which he and the military suspected to shelter rebels and teach subversion. Additionally, the military and the NTF-ELCAC were denounced after they cited clandestine recruitment activities by the communist rebels within university campuses nationwide, notably in both state-run University of the Philippines and Polytechnic University of the Philippines. Several human rights organizations called on the succeeding Bongbong Marcos administration to abolish the NTF-ELCAC due to continued red-tagging allegations; the calls, however, were later rejected by Marcos.
=== Magic Pill (2024) === Magic Pill: The Extraordinary Benefits and Disturbing Risks of the New Weight Loss Drugs, Hari's first-person account of taking the weight loss drug Ozempic (semaglutide), was published in 2024. The book also documents the history of the medication. According to Hari, while there are health benefits to taking Ozempic for some users, there are also potential risks. Hari falsely claimed in Magic Pill that restaurant critic Jay Rayner had taken semaglutide and the book included false statements about Rayner's opinion of the drug. Rayner had previously written that he would never take the drug, and described Hari's description as "very much defamatory". Hari apologized for the error. In a review for The Guardian, science writer Tom Chivers found several misuses of references that did not support the book's claims, as well as scientific inaccuracies. A fact check by The Daily Telegraph found six examples of "errors, outdated data and disputed claims". Hari said these errors would be corrected in future editions. Magic Pill has been translated into French and Russian.
Sources: en.wikipedia.org
=== Category:EC 3.3 (act on ether bonds) === Category:EC 3.3 Adenosylmethionine hydrolase S-adenosyl-L-homocysteine hydrolase Alkenylglycerophosphocholine hydrolase Alkenylglycerophosphoethanolamine hydrolase Cholesterol-5,6-oxide hydrolase Hepoxilin-epoxide hydrolase Isochorismatase Leukotriene-A4 hydrolase Limonene-1,2-epoxide hydrolase Microsomal epoxide hydrolase Trans-epoxysuccinate hydrolase
De novo or ab initio techniques for computational protein structure prediction can be used for simulating various aspects of protein folding. The earliest computer simulation of protein folding was performed in 1975 by Levitt and Warshel (Nature 1975) produced folding paths that collapsed to a structure close to the folded structure and basically provided a "resolution" of the Leventhal paradox. The simulation also involved a normal mode treatment that explored some of the dynamical aspects of the folding process. Molecular dynamics (MD) was used in simulations of protein folding and dynamics in silico. First equilibrium folding simulations were done using implicit solvent model and umbrella sampling. Because of computational cost, ab initio MD folding simulations with explicit water are limited to peptides and small proteins. MD simulations of larger proteins remain restricted to dynamics of the experimental structure or its high-temperature unfolding. Long-time folding processes (beyond about 1 millisecond), like folding of larger proteins (>150 residues) can be accessed using coarse-grained models. Several large-scale computational projects, such as Rosetta@home, Folding@home and Foldit, target protein folding. Long continuous-trajectory simulations have been performed on Anton, a massively parallel supercomputer designed and built around custom ASICs and interconnects by D. E. Shaw Research. The longest published result of a simulation performed using Anton as of 2011 was a 2.936 millisecond simulation of NTL9 at 355 K.
A number of gaseous or highly volatile brominated halomethane compounds are non-toxic and make superior fire suppressant agents by this same mechanism, and are particularly effective in enclosed spaces such as submarines, airplanes, and spacecraft. However, they are expensive and their production and use has been greatly curtailed due to their effect as ozone-depleting agents. They are no longer used in routine fire extinguishers, but retain niche uses in aerospace and military automatic fire suppression applications. They include bromochloromethane (Halon 1011, CH2BrCl), bromochlorodifluoromethane (Halon 1211, CBrClF2), and bromotrifluoromethane (Halon 1301, CBrF3).
There are many formats of BsAbs, but the two main categories are IgG-like and non-IgG-like. The main types of manufacturing methods are quadromas, chemical conjugation, and genetic recombination, and each method results in a unique format.
Sources: en.wikipedia.org
=== EC 1.14.20 With 2-oxoglutarate as one donor, and the other dehydrogenated === EC 1.14.20.1: deacetoxycephalosporin-C synthase EC 1.14.20.2: Now EC 1.14.11.59, 2,4-dihydroxy-1,4-benzoxazin-3-one-glucoside dioxygenase EC 1.14.20.3: (5R)-carbapenem-3-carboxylate synthase EC 1.14.20.4: anthocyanidin synthase EC 1.14.20.5: flavone synthase I EC 1.14.20.6: flavonol synthase EC 1.14.20.7: 2-oxoglutarate/L-arginine monooxygenase/decarboxylase (succinate-forming) EC 1.14.20.8: (–)-deoxypodophyllotoxin synthase EC 1.14.20.9: L-tyrosine isonitrile desaturase EC 1.14.20.10: L-tyrosine isonitrile desaturase/decarboxylase EC 1.14.20.11: 3-[(Z)-2-isocyanoethenyl]-1H-indole synthase EC 1.14.20.12: 3-[(E)-2-isocyanoethenyl]-1H-indole synthase EC 1.14.20.13: 6β-hydroxyhyoscyamine epoxidase EC 1.14.20.14: hapalindole-type alkaloid chlorinase EC 1.14.20.15: L-threonyl-[L-threonyl-carrier protein] 4-chlorinase
== Structure == The body of the penis is suspended from the pubic symphysis by the suspensory ligament, part of the deep fascia arising from the anterior surface of the symphysis. It has two surfaces; the dorsal and the ventral or urethral. The penile raphe runs on its ventral surface. The body is surrounded by a bi-layered model of tunica albuginea in which a distal ligament buttresses the glans penis and plays an integral role in the penile fibroskeleton, and the structure is called "os analog", a term coined by Geng Long Hsu in the Encyclopedia of Reproduction. The human penis differs from those of most other mammals in having no baculum (or erectile bone), relying exclusively on engorgement with blood to reach its erect state; the loss of the baculum in the human lineage has been linked to changes in mating pattern. A shallow groove, which marks their junction on the upper surface lodges the deep dorsal vein of the penis, which is flanked by a pair of cavernosal veins of the penis, while a deeper and wider groove between them on the surface below contains the corpus spongiosum. The body is ensheathed by fascia, which includes tunica albuginea, Buck's fascia, dermis, and skin.
Bodybuilding is the practice of progressive resistance exercise to build, control, and develop one's muscles via hypertrophy. An individual who engages in this activity is referred to as a bodybuilder. It is primarily undertaken for aesthetic purposes over functional ones, distinguishing it from similar activities such as powerlifting and calisthenics. In competitive bodybuilding, competitors appear onstage in line-ups and perform specified poses (and later individual posing routines) for a panel of judges who rank them based on conditioning, muscularity, posing, size, stage presentation, and symmetry. Bodybuilders prepare for competitions by exercising and eliminating non-essential body fat. This is enhanced at the final stage by a combination of carbohydrate loading and dehydration to achieve maximum muscle definition and vascularity. Most bodybuilders also tan and shave their bodies prior to competition.
The band posted a tribute to him on their website in September 2022. In 2023, Johnston, McDonald, and Simmons (as the Doobie Brothers) were nominated for induction into the Songwriters Hall of Fame. In addition, a continuation of their 50th Anniversary tour was planned for the year. The Doobies started their 2023 touring schedule in Australia and Japan in April before making their way to Hawaii and then returning to the continental U.S. in May. Three days before they were set to perform in Hollywood, Florida, the band released a statement that Tom Johnston would be undergoing surgery following severe back pain and would not be able to join the band on the upcoming leg of the 50th Anniversary Tour. Simmons, McDonald, and McFee continued the 2023 touring schedule in Johnston's absence. Lead vocals normally performed by Johnston were shared between Simmons, McDonald, and bassist John Cowan. In June 2023, Simmons said in an interview that the band will be releasing new music the next year with McDonald. The band opened for the Eagles on the latter's The Long Goodbye Tour in November 2023, replacing Steely Dan due to Donald Fagen's health issues. On November 17, 2023, the Doobie Brothers released a new single entitled "Lahaina" to benefit the families and individuals affected by the 2023 Hawaii wildfires. The song, produced by John Shanks, features Mick Fleetwood on drums, Jake Shimabukuro on ukulele, and Henry Kapono on vocals. In 2024 a fully healed Tom Johnston rejoined the Doobies, who continued on with their 50th Anniversary tour.
When simple salts dissolve, they dissociate into individual ions, which are solvated and dispersed throughout the resulting solution. Salts do not exist in solution. In contrast, molecular compounds, which includes most organic compounds, remain intact in solution. The solubility of salts is highest in polar solvents (such as water) or ionic liquids, but tends to be low in nonpolar solvents (such as petrol/gasoline). This contrast is principally because the resulting ion–dipole interactions are significantly stronger than ion-induced dipole interactions, so the heat of solution is higher. When the oppositely charged ions in the solid ionic lattice are surrounded by the opposite pole of a polar molecule, the solid ions are pulled out of the lattice and into the liquid. If the solvation energy exceeds the lattice energy, the negative net enthalpy change of solution provides a thermodynamic drive to remove ions from their positions in the crystal and dissolve in the liquid. The enthalpy change of solution is usually positive for most solid solutes like salts, which means that their solubility increases when the temperature increases. There are some unusual salts such as calcium hydroxide, where this enthalpy change is negative and the solubility decreases with temperature. The lattice energy, the cohesive forces between these ions within a solid, determines the solubility. The solubility is dependent on how well each ion interacts with the solvent, so certain patterns become apparent. For example, salts of sodium, potassium and ammonium are usually soluble in water.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.